Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label (Q87261695)
Jump to navigation
Jump to search
scientific article published on 11 February 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label |
scientific article published on 11 February 2014 |
Statements
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials (English)
Yukio Tanizawa
Kohei Kaku
Eiichi Araki
Kazuyuki Tobe
Yasuo Terauchi
Kazunori Utsunomiya
Yasuhiko Iwamoto
Wataru Ohtsuka
Daisuke Watanabe
Hideki Suganami
Tofogliflozin 004 and 005 Study group